Home › Ovarian Epithelial Carcinoma › NCT06756035
CT-95 in Advanced Cancers Associated With Mesothelin Expression
RecruitingPhase 1
Phase 1a/1b Study of CT-95 in Advanced Cancers Associated With Mesothelin Expression
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * ECOG 0 or 1 * Subjects with evaluable disease per RECIST 1.1 or mRECIST * Subjects with adequate organ function. * Subjects with advanced cancers associated with mesothelin expression Exclusion Criteria: * Uncontrolled significant active infection or any medical or other condition that in opinion of the investigator would preclude the subject's participation in the study. * Prior treatment with MSLN-targeted CD3 or chimeric antigen receptor T cell (CAR-T) therapy * Concurrent participation in another investigational clinical trial. * Evidence of leptomeningeal disease
About the study
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with MSLN expression.
What is being tested
- CT-95 (drug)
Sponsor: Context Therapeutics Inc. · Participants: 70 · Started: Mar 31, 2025
Contact the study team
- Context Clinical Development · Phone: 267-225-7416
Official record on ClinicalTrials.gov — NCT06756035
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.